Insider · CIK 0001913897

Boyle Scott N

Reports to the SEC for 1 company · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001913897

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-14	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−7,269 sh	$1.89	−$13.7K	298,801
2026-02-14	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+21K sh	—	—	306,070
2026-02-13	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+5,000 sh	—	—	307,805
2026-02-13	CCCCC4 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+200K sh	—	—	307,805
2026-02-13	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,735 sh	$1.89	−$3,279.15	306,070
2025-02-18	CCCCC4 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−669 sh	$3.15	−$2,107.35	107,805
2025-02-14	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−2,368 sh	$3.18	−$7,530.24	108,474
2025-02-14	CCCCC4 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+56.5K sh	—	—	111,332
2025-02-14	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+84.7K sh	—	—	84,700
2025-02-14	CCCCC4 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−490 sh	$3.15	−$1,543.5	110,842
2025-02-13	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,735 sh	$3.20	−$5,552	54,832
2024-11-07	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+3,750 sh	—	—	57,669
2024-11-07	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,102 sh	$6.04	−$6,656.08	56,567
2024-11-07	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−3,750 sh	—	—	10,500
2024-09-16	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+2,250 sh	—	—	54,580
2024-09-16	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−2,250 sh	—	—	14,250
2024-09-16	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−661 sh	$6.36	−$4,203.96	53,919
2024-03-07	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Business Officer	DDisposition to Issuer	−115K sh	—	—	0
2024-03-07	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+115K sh	—	—	115,000
2024-02-14	CCCCC4 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+27.3K sh	—	—	52,330
2024-02-14	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+123K sh	—	—	122,800
2024-02-13	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,735 sh	$6.53	−$11.3K	25,030
2023-09-18	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+120K sh	—	—	120,000
2023-08-30	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−2,250 sh	—	—	16,500
2023-08-30	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−661 sh	$2.93	−$1,936.73	26,765
2023-08-30	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+2,250 sh	—	—	27,426
2023-02-13	CCCCC4 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+20K sh	—	—	25,176
2023-02-13	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+90K sh	—	—	90,000
2023-01-30	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−3,750 sh	—	—	18,750
2023-01-30	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,222 sh	$7.78	−$9,507.16	5,176
2023-01-30	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+3,750 sh	—	—	6,398
2022-05-26	CCCCC4 Therapeutics, Inc.F Tax Payment	Chief Business Officer	FTax Payment	−1,102 sh	$7.01	−$7,725.02	2,648
2022-05-25	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−3,750 sh	—	—	22,500
2022-05-25	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+3,750 sh	—	—	3,750

Recent filings

Accepted (ET)
Feb 184
Boyle Scott N0001470831-26-000180
SEC(opens sec.gov)
Feb 184
Boyle Scott N0001662579-25-000019
SEC(opens sec.gov)
Nov 124
Boyle Scott N0001662579-24-000104
SEC(opens sec.gov)
Sep 174
Boyle Scott N0001662579-24-000083
SEC(opens sec.gov)
Mar 84
Boyle Scott N0001662579-24-000032
SEC(opens sec.gov)
Feb 154
Boyle Scott N0001662579-24-000015
SEC(opens sec.gov)

Companies

C4 Therapeutics, Inc.Chief Business OfficerCCCC

Address

C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #120

WATERTOWN, MA, 02472